Deucravacitinib (BMS-986165) for Pityriasis Rubra Pilaris

Part of paid clinical trials in Scottsdale, Arizona.

Sponsor
Mayo Clinic
Study ID
NCT06444399
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Pityriasis Rubra Pilaris

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to evaluate the safety and effectiveness of Deucravacitinib (BMS-986165) in Pityriasis Rubra Pilaris as assessed by the change in Investigator Global Assessment (IGA), PASI- 50, 75, 90, DLQI, NRS itch, and Skindex-16 at week 24. To predict responses through the identification of unique biomarkers of PRP utilizing single-cell RNA sequencing.

Key Dates

Start date
Jul 29, 2024
Status verified
Feb 2026
Primary completion
Sep 2, 2025
Completion
Jul 1, 2026

Study Design

Enrollment
12 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Pityriasis Rubra Pilaris
    Subjects will receive Deucravacitinib, twice daily for 24 weeks

Primary Outcome Measure

Change in PASI scores [ Time Frame: Baseline, 24 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Mayo Clinic in ArizonaScottsdaleArizona85259-

Find similar trials in Scottsdale, AZ

By research site
Mayo Clinic in Arizona· Scottsdale, AZ

Related Studies